Lamivudine for patients with chronic hepatitis B and advanced liver disease.
暂无分享,去创建一个
Oliver N Keene | J. Sung | Y. Liaw | O. Keene | G. Farrell | T. Tanwandee | J. Dixon | Joseph J Y Sung | Cha‐Ze Lee | Yun-Fan Liaw | Wan Cheng Chow | Cha-Ze Lee | Geoffrey Farrell | Hon Yuen | Tawesak Tanwandee | Qi-Min Tao | Kelly Shue | Jonathan S Dixon | D Fraser Gray | Jan Sabbat | W. Chow | H. Yuen | D. Gray | Qihui Tao | K. Shue | J. Sabbat
[1] William M. Lee,et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.
[2] M. Colombo,et al. Long‐Term suppression of hepatitis B e antigen‐negative chronic hepatitis B by 24‐month interferon therapy , 2003, Hepatology.
[3] Ching-Lung Lai,et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] Y. Liaw,et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update * , 2003, Journal of gastroenterology and hepatology.
[5] L. Rodrigo,et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis , 2003, Hepatology.
[6] B. Rehermann,et al. Chronic hepatitis B and hepatocarcinogenesis: Does prevention of “collateral damage” bring the cure? , 2003, Hepatology.
[7] R. Fontana. Management of Patients with Decompensated HBV Cirrhosis , 2003, Seminars in liver disease.
[8] E. Schiff,et al. Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.
[9] Chien-Jen Chen,et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.
[10] H. Chiou,et al. Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B , 2002, Hepatology.
[11] J. George,et al. Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. , 2002 .
[12] B. McMahon,et al. Chronic hepatitis B , 2001, Hepatology.
[13] M. Yuen,et al. Long‐term follow‐up of interferon alfa treatment in chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis‐related complications , 2001, Hepatology.
[14] N. Leung,et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.
[15] E. Schiff,et al. A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B , 2001, Hepatology.
[16] E. Schiff,et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.
[17] C. Chu,et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.
[18] C. Chu,et al. Long‐term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection , 1999, Hepatology.
[19] N. Leung,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.
[20] D. Häussinger,et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.
[21] E. Christensen,et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study , 1994 .
[22] P. Lachenbruch,et al. The Design and Analysis of Sequential Clinical Trials (2nd ed.). , 1993 .
[23] J. Hoofnagle,et al. Hepatitis B-related end-stage liver disease. , 1992, Gastroenterology.
[24] R. D. de Man,et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. , 1992, Gastroenterology.
[25] G. Fattovich,et al. Natural history and prognostic factors for chronic hepatitis type B. , 1991, Gut.
[26] C. Chu,et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. , 2008, Liver.
[27] R. Beasley. Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.
[28] C. Chu,et al. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study , 1988, Hepatology.
[29] J Whitehead,et al. A FORTRAN program for the design and analysis of sequential clinical trials. , 1983, Computers and biomedical research, an international journal.
[30] T. Merigan,et al. Survival in chronic hepatitis B. An analysis of 379 patients. , 1984, Annals of internal medicine.
[31] Y. Liaw,et al. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. , 1982, The Journal of infectious diseases.
[32] L. Freedman. Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.
[33] Lu-Yu Hwang,et al. HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.
[34] D. Cox. Regression Models and Life-Tables , 1972 .